PLEASANTON, Calif., Dec. 12,
2023 /PRNewswire/ -- Movano Health (Nasdaq:
MOVE), a pioneer in health technology, today announced that
following the successful results of its recent blood pressure
clinical trial it will be holding in person demonstrations of live
waveforms at both the 2024 CES Show in Las Vegas January 8-11,
2024 and in conjunction with the JP Morgan Healthcare
Conference in San Francisco
January 9-10, 2024.
Designed to showcase Movano Health's System on a Chip (SoC) and
illustrate the strategic ways this technology can be implemented to
monitor multiple chronic conditions, these events will be an
opportunity for prospective partners to experience the efficacy of
the recent clinical trial results and, if desired, under NDA review
the development roadmap.
"The response to our recent blood pressure clinical trial
results has far exceeded our expectations and as we transition to
the next phase of development including undergoing critical pivotal
trials, we believe it is the right time to open up the conversation
to potential partners," said Michael
Leabman, CTO and Founder of Movano Health. "Our goal is to
significantly accelerate the development and commercialization of
this technology and help millions of people as quickly as
possible."
During the recent trial, Movano Health's cuffless prototype
showed a level of accuracy within the standards recognized by the
FDA for blood pressure monitoring devices. The prototype achieved
an overall mean absolute difference (MAD) of 5.9 mmHg, which is
below the 7 mmHg MAD required per a standard for wearable, cuffless
blood pressure measuring devices (IEEE1708a-2019). Movano Health is
also evaluating AI-based individual calibration methods to further
enhance the future performance of the device.
Movano Health's ultra-compact System-on-a-Chip (SoC) measures
just 4 x 6.7mm and is the culmination of five years of intensive
research, centering on advanced mmWave Radio Frequency (RF) and AI
technology, leading to 23 issued patents and 31 pending.
"Blood pressure monitoring will be a significant addition to the
suite of analytes we currently offer in our recently launched
product, the Evie Ring", said John
Mastrototaro, CEO of Movano Health. "We are excited to
continue to build a robust data collection and evaluation solution
to help people take better care of their overall health."
For more information about participating in the blood pressure
partnership forum, please contact Michael
Soule, VP of Business Development, at msoule@movano.com as
soon as possible, as time slots will fill up quickly.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health
is developing a suite of purpose-driven healthcare solutions to
bring medical-grade, high-quality data to the forefront of consumer
health devices. Featuring modern form factors, Movano Health's
devices capture a comprehensive picture of a person's vital health
information and uniquely translate the data into personalized and
intelligent insights that empower consumers to live healthier and
more balanced lives. Movano Health's end-to-end solutions will soon
enable consumers and their healthcare professionals to utilize
daily medical-grade data as a tool to proactively monitor and
manage health outcomes. For more information on Movano
Health, visit https://movanohealth.com/.
Forward Looking Statements
This press release contains forward-looking statements concerning
our expectations, anticipations, intentions, beliefs, or strategies
regarding the future. These forward-looking statements are based on
assumptions that we have made as of the date hereof and are subject
to known and unknown risks and uncertainties that could cause
actual results, conditions, and events to differ materially from
those anticipated. Therefore, you should not place undue reliance
on forward-looking statements. Examples of forward-looking
statements include, among others, statements we make regarding
plans with respect to commercial launch of the Evie Ring; planned
cost-cutting initiatives; anticipated FDA clearance for the Evie
Ring and other products in development; expected future operating
results; product development and features, product releases,
clinical trials and regulatory initiatives; our strategies,
positioning and expectations for future events or performance.
Important factors that could cause actual results to differ
materially from those in the forward-looking statements are set
forth in our most recent Annual Report on Form 10-K and any
subsequent Quarterly Reports on Form 10-Q, and in our other reports
filed with the Securities and Exchange Commission, including under
the caption "Risk Factors." Any forward-looking statement in
this release speaks only as of the date of this release. We
undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/movano-health-announces-blood-pressure-partnership-forum-following-significant-response-to-groundbreaking-accuracy-achievement-302012561.html
SOURCE Movano